243 related articles for article (PubMed ID: 29921944)
1. Getting to the brain.
Baratta MG
Nat Nanotechnol; 2018 Jul; 13(7):536. PubMed ID: 29921944
[No Abstract] [Full Text] [Related]
2. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Lam FC; Morton SW; Wyckoff J; Vu Han TL; Hwang MK; Maffa A; Balkanska-Sinclair E; Yaffe MB; Floyd SR; Hammond PT
Nat Commun; 2018 May; 9(1):1991. PubMed ID: 29777137
[TBL] [Abstract][Full Text] [Related]
3. A local combination therapy to inhibit GBM recurrence.
Schwendeman SP
J Control Release; 2019 Sep; 309():339-340. PubMed ID: 31437469
[No Abstract] [Full Text] [Related]
4. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.
Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X
Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy.
Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ
Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
7. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
8. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
9. Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.
Zhao M; Bozzato E; Joudiou N; Ghiassinejad S; Danhier F; Gallez B; Préat V
J Control Release; 2019 Sep; 309():72-81. PubMed ID: 31306678
[TBL] [Abstract][Full Text] [Related]
10. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
11. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
12. Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment.
Gabay M; Weizman A; Zeineh N; Kahana M; Obeid F; Allon N; Gavish M
Cell Mol Neurobiol; 2021 Jul; 41(5):1019-1029. PubMed ID: 33025416
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma.
Locatelli E; Naddaka M; Uboldi C; Loudos G; Fragogeorgi E; Molinari V; Pucci A; Tsotakos T; Psimadas D; Ponti J; Franchini MC
Nanomedicine (Lond); 2014 May; 9(6):839-49. PubMed ID: 24433240
[TBL] [Abstract][Full Text] [Related]
14. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.
Rundle-Thiele D; Head R; Cosgrove L; Martin JH
Br J Clin Pharmacol; 2016 Feb; 81(2):199-209. PubMed ID: 26374633
[TBL] [Abstract][Full Text] [Related]
15. How could a drug used to treat alcoholism also be effective against glioblastoma?
Wang W; Darling JL
Expert Rev Anticancer Ther; 2013 Mar; 13(3):239-41. PubMed ID: 23477507
[No Abstract] [Full Text] [Related]
16. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
Ganipineni LP; Danhier F; Préat V
J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex.
Kang T; Jiang M; Jiang D; Feng X; Yao J; Song Q; Chen H; Gao X; Chen J
Mol Pharm; 2015 Aug; 12(8):2947-61. PubMed ID: 26149889
[TBL] [Abstract][Full Text] [Related]
18. Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier.
Monaco I; Camorani S; Colecchia D; Locatelli E; Calandro P; Oudin A; Niclou S; Arra C; Chiariello M; Cerchia L; Comes Franchini M
J Med Chem; 2017 May; 60(10):4510-4516. PubMed ID: 28471660
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Rezaei V; Rabiee A; Khademi F
J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
[TBL] [Abstract][Full Text] [Related]
20. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
Gan CW; Feng SS
Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
